The President’s Emergency Plan for AIDS Relief (PEPFAR) is a United States government initiative established in 2003 to support the international response to HIV/AIDS. It finances antiretroviral treatment, HIV testing and prevention, services for children and families affected by the epidemic, and the laboratories, workforces, and information systems needed to deliver those services. Although its largest investments have been in sub-Saharan Africa, its activities extend to other regions. PEPFAR is principally a bilateral assistance program, working through partner governments and implementing organizations, while also encompassing U.S. support for multilateral HIV institutions.
PEPFAR was created when effective HIV treatment was widely available in wealthy countries but remained inaccessible to most people with HIV in low-income countries. Its initial emergency mission developed into a long-term effort to reduce HIV-related illness, deaths, and new infections. By the end of fiscal year 2023, the program reported supporting antiretroviral treatment for approximately 20.5 million people. Its history encompasses changes in treatment science, prevention policy, international financing, and the organization of public health services.
Origins and legislative development
The immediate background to PEPFAR was the severe international treatment gap at the beginning of the twenty-first century. Combination antiretroviral therapy had sharply reduced AIDS mortality in countries able to provide it from the mid-1990s onward. In much of sub-Saharan Africa, however, high medicine prices, limited laboratory capacity, shortages of trained health workers, and weak procurement systems restricted access. HIV-related illness placed growing pressure on hospitals, households, and national economies. Prevention programs existed, but treatment at population scale remained exceptional.
Several developments preceded the initiative. Activism by people living with HIV and treatment-access organizations increased pressure for affordable medicines. Generic competition and negotiated price reductions lowered antiretroviral prices. The United Nations General Assembly held a special session on HIV/AIDS in 2001, and the Global Fund to Fight AIDS, Tuberculosis and Malaria began operating in 2002. These developments helped establish the political and institutional conditions for a much larger international response.
President George W. Bush announced PEPFAR in his State of the Union address on January 28, 2003. He proposed a five-year, US$15 billion commitment, including support for the Global Fund. Congress enacted the United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003, which Bush signed on May 27. The initiative’s original goals were to support treatment for 2 million people, prevent 7 million new HIV infections, and provide care for 10 million people affected by HIV/AIDS, including orphans and vulnerable children.
The initial strategy concentrated resources in 15 focus countries: Botswana, Côte d’Ivoire, Ethiopia, Guyana, Haiti, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda, Vietnam, and Zambia. These countries were not the entire geographic scope of U.S. HIV assistance, but they received particular attention under the early emergency model. The selection included countries with large epidemics, substantial unmet need, and opportunities for rapid expansion of services.
Congress subsequently revised and extended the legislative framework. The 2008 Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act authorized up to US$48 billion over five years for the broader international HIV, tuberculosis, and malaria response. Further legislation in 2013 and 2018 extended selected authorities and oversight provisions. These authorizations did not themselves constitute annual spending: Congress separately appropriates money. This distinction is important because the expiration of particular time-limited provisions is not equivalent to the automatic termination of every PEPFAR activity.
Governance, financing, and country partnerships
PEPFAR is not a single service-delivery agency. It is an interagency program coordinated through the Department of State by the U.S. Global AIDS Coordinator, a position created by the 2003 legislation. The coordinator provides strategic direction, oversees resource allocation, and coordinates the work of participating agencies. In 2023, the Department of State incorporated this leadership function into its Bureau of Global Health Security and Diplomacy, reflecting the initiative’s relationship to wider international health cooperation.
The U.S. Agency for International Development and the Centers for Disease Control and Prevention have been major implementing agencies. USAID has supported service delivery, procurement, community organizations, and institutional development. CDC has contributed expertise in epidemiology, laboratories, surveillance, and clinical programs. Other participants have included the Department of Defense, the Health Resources and Services Administration, and the Peace Corps. Their roles differ by country and activity; PEPFAR’s coordination structure does not erase their separate statutory responsibilities or contracting arrangements.
Much implementation occurs through grants, cooperative agreements, and contracts with ministries, universities, nongovernmental organizations, faith-based providers, and private-sector organizations. A single national HIV program may therefore combine domestically financed staff, PEPFAR-supported technical assistance, Global Fund-financed commodities, and services delivered by several kinds of institution. Understanding this shared production of services is essential when interpreting claims about which organization “supports” a clinic or treatment cohort.
Country Operational Plans, commonly called COPs, have been central instruments for planning bilateral programs. Regional Operational Plans serve a related function for some regional portfolios. Planning establishes priorities, budgets, geographic emphasis, implementing arrangements, and expected results. Consultations involve U.S. country teams, partner governments, implementing organizations, and civil-society representatives. The plans translate broad objectives into decisions about facilities, populations, laboratory networks, and community services, although the precise planning procedures have changed over time.
PEPFAR financing combines emergency-assistance origins with the recurring obligations of long-term care. Antiretroviral treatment must continue over many years, whereas grants and appropriations operate through limited budget periods. This creates a structural need to connect annual health financing with predictable procurement and service continuity. Announced funding, congressional authorization, appropriation, obligation, and actual expenditure describe different stages and should not be treated as interchangeable.
Coordination with national authorities also raises questions of ownership and accountability. Partner governments determine national treatment guidelines and organize public services, while U.S. agencies remain accountable for the use of American public funds. Country planning consequently involves reconciling national strategies with donor requirements, reporting systems, and procurement rules. The resulting arrangements vary substantially between countries with large domestic HIV budgets and those that rely heavily on external assistance.
Antiretroviral treatment and clinical care
The expansion of antiretroviral therapy has been PEPFAR’s most prominent clinical activity. HIV replicates through several molecular stages, and antiretroviral medicines interrupt those stages. Combination treatment suppresses viral replication, allows partial recovery of the immune system, and reduces the risk of AIDS-related illness and death. It does not eradicate HIV, so maintaining access and continuity is fundamental to the clinical model.
Early implementation required more than purchasing medicines. Programs established treatment sites, trained clinicians and nurses, organized patient records, strengthened medicine distribution, and supported management of advanced HIV disease. Cotrimoxazole prophylaxis and diagnosis and treatment of opportunistic infections were important components of care. Services also addressed tuberculosis, a major cause of illness and death among people with HIV, through screening, diagnostic testing, preventive treatment, and coordination of HIV and tuberculosis therapy.
Treatment eligibility broadened as scientific evidence and international guidelines changed. Early programs commonly used clinical stage and CD4-cell counts to determine when treatment should begin. Evidence increasingly supported earlier initiation, and in 2015 the World Health Organization recommended antiretroviral therapy for everyone living with HIV regardless of CD4 count. PEPFAR-supported programs subsequently expanded “test and treat” approaches in coordination with national policies. This changed the task from identifying only those with advanced disease to diagnosing infection earlier and linking all diagnosed people to sustained care.
Treatment regimens also evolved. Older combinations often had greater toxicity, more complicated dosing, or lower barriers to resistance than later options. Increasing use of fixed-dose combinations reduced pill burden. Dolutegravir-containing regimens became widely adopted in many supported countries because of their antiviral potency, tolerability, and resistance profile. Procurement and guideline changes required coordination: introducing a new regimen involved forecasting demand, modifying training, managing remaining stock, and ensuring that appropriate formulations were available for different age groups.
Viral-load testing became a central measure of treatment response. Unlike a CD4 count, which describes immune status, a viral-load result measures the amount of circulating HIV genetic material. Persistent detectable virus can indicate interrupted access, difficulty taking treatment, or drug resistance. Programs therefore combine testing with follow-up systems rather than treating the laboratory result as an isolated endpoint. Specimen transport, result return, and clinical action are all necessary for testing to improve care.
Service delivery increasingly incorporates differentiated care, including longer medicine refills, community collection points, and less frequent clinical visits for people established on treatment. These arrangements can reduce travel costs and clinic congestion while preserving clinical review when needed. Children and adolescents present additional challenges involving diagnosis, suitable formulations, disclosure, caregiver support, and transition to adult care. As treated populations age, integration with primary health care and management of noncommunicable diseases become more important.
HIV prevention and prevention of vertical transmission
PEPFAR’s prevention portfolio has changed with the evidence base and the epidemic in each country. Its early policy framework emphasized abstinence, fidelity, and condom use, often described as “ABC.” The original legislation included spending provisions that directed a share of prevention funding toward abstinence-until-marriage activities. Later legislation changed these requirements, and the program’s prevention portfolio expanded to include a broader range of biomedical, behavioral, and structural interventions. These activities differ in the populations they serve and in the evidence used to assess them.
HIV testing is both a diagnostic service and an entry point into prevention and treatment. Facility-based testing, community outreach, partner services, and HIV self-testing can reach different groups. Testing strategies must distinguish between detecting infections and achieving meaningful linkage: a positive result has limited programmatic value if treatment is inaccessible, while a negative result can create an opportunity to offer prevention services. Consent, confidentiality, accurate testing algorithms, and appropriate follow-up are therefore integral to implementation.
Prevention of vertical transmission—transmission during pregnancy, childbirth, or breastfeeding—has been a major component from the initiative’s early years. Services connect antenatal HIV testing with maternal treatment, infant prophylaxis, feeding counseling consistent with national guidance, and early infant diagnosis. Because maternal antibodies can persist in an infant’s blood, diagnosing HIV in early infancy requires virological methods rather than relying solely on standard antibody tests. Follow-up must extend beyond delivery when breastfeeding continues.
By fiscal year 2023, PEPFAR reported that its activities had enabled approximately 5.5 million babies to be born HIV-free to mothers living with HIV since the program began. This cumulative measure describes outcomes associated with supported services; it is not a direct count of infections experimentally proven to have been prevented. Maternal retention in care and repeat testing where indicated remain important because infection acquired during pregnancy or breastfeeding can carry substantial transmission risk.
Voluntary medical male circumcision became another major intervention following randomized trials in South Africa, Kenya, and Uganda, reported in 2005–2007. These trials found an approximately 50–60 percent reduction in heterosexual HIV acquisition among circumcised men over the studied follow-up periods. Programs combine the procedure with counseling, testing, wound-care information, and other prevention services. The intervention provides partial protection and does not substitute for other measures.
Pre-exposure prophylaxis, or PrEP, added an option for HIV-negative people at substantial risk. Its effectiveness depends on the product and on receiving it as required. PEPFAR-supported prevention also includes condoms, sexually transmitted infection services, and targeted outreach. Treatment itself contributes to prevention: sustained viral suppression prevents sexual HIV transmission. This effect links individual clinical success to population-level prevention, while making continued treatment access and reliable viral-load monitoring especially consequential.
Populations, community services, and social conditions
The distribution of HIV is shaped by biology, sexual and injecting networks, access to services, and the social determinants of health. Consequently, uniform provision of identical services does not necessarily produce equal access. PEPFAR programs have used geographically and population-focused approaches to address differences between districts, age groups, and social groups. National prevalence alone can conceal localized epidemics or gaps in diagnosis and treatment.
Children affected by HIV were an explicit priority in the original legislation. Programs for orphans and vulnerable children developed beyond the provision of material assistance alone to include household assessment, education-related support, caregiver services, protection referrals, and links to HIV testing and care. Children can be affected through their own infection, parental illness or death, reduced household income, or disrupted schooling. These pathways make coordination between health services and social-service systems important.
Adolescent girls and young women have been a particular focus in parts of eastern and southern Africa, where HIV acquisition has been substantially higher than among male peers in many settings. PEPFAR launched the DREAMS partnership in 2014; its name stands for Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe. Implementation began in selected high-burden settings, combining interventions such as HIV prevention, social support, educational assistance, and services addressing gender-based violence. The package reflects the fact that no single intervention addresses all pathways of risk.
Services for men and boys address a different pattern of gaps. In many settings, men have been less likely than women to know their HIV status or remain engaged with routine clinic services. Community testing, extended opening hours, workplace approaches, and male-focused outreach have been used to improve access. These interventions illustrate why service design depends not only on clinical eligibility but also on working hours, mobility, expectations about care, and the practical costs of attending facilities.
Key populations—including sex workers, gay men and other men who have sex with men, transgender people, people who inject drugs, and people in prisons and other closed settings—may face high HIV exposure alongside barriers to care. The relevance and size of each population differ by country. Criminalization, discrimination, violence, and concerns about disclosure can affect access to prevention and treatment. Community-led organizations can provide peer outreach, navigation, and feedback that conventional facility systems may not obtain.
Community participation also has an accountability role. Networks of people living with HIV and other civil-society organizations have participated in country planning and community-led monitoring. Such monitoring can document medicine stockouts, inaccessible clinic hours, confidentiality failures, or informal charges. Its purpose differs from routine facility reporting: it examines how services are experienced and whether formal availability translates into usable care. Data privacy is especially important when collecting information that could expose a person’s HIV status or membership in a stigmatized population.
Medicines, laboratories, and health-system capacity
PEPFAR’s treatment scale-up required changes in international pharmaceutical procurement. At its launch, the price and limited supply of antiretroviral medicines were major constraints. In 2004, the U.S. Food and Drug Administration established an expedited review pathway for antiretroviral products intended for use in PEPFAR programs. Products could receive tentative approval when they met relevant quality, safety, and efficacy standards but could not yet be marketed in the United States because of patent or exclusivity restrictions. This helped make quality-assured generic products available for procurement.
Lower medicine prices increased the number of people who could be treated within a given budget, but purchase price was only one component of delivery. Effective supply chains require demand forecasting, competitive purchasing, storage, inventory management, customs clearance, and distribution to dispensing sites. Stockouts can interrupt therapy even when sufficient funding exists at the national level. Conversely, inaccurate forecasts can lead to overstocking and expiry, particularly when countries change regimens or when pediatric formulations have relatively small and variable demand.
Laboratory investments have included HIV diagnostic testing, CD4 testing, viral-load testing, early infant diagnosis, and tuberculosis diagnostics. These services depend on equipment maintenance, trained staff, reagents, quality assurance, and specimen transport. A functioning central laboratory does not by itself create access for a remote clinic. Systems must move specimens reliably and return results in time for clinical decisions. Laboratory network planning therefore connects technology choices with geography and transport infrastructure.
Workforce development has included clinical training, mentorship, laboratory training, and support for management functions. Task sharing—assigning defined responsibilities to appropriately trained nurses, other nonphysician clinicians, or community workers—helped expand treatment where physicians were scarce. Such arrangements require supervision, referral pathways, and professional standards. They are organizational responses to workforce constraints rather than simple substitutions of one occupation for another.
PEPFAR also supported electronic health records, reporting systems, and public health surveillance. Facility data can reveal treatment interruptions, gaps in viral-load testing, or uneven performance between districts. Population-based surveys add information about people who do not attend facilities. The Population-based HIV Impact Assessment, or PHIA, surveys have measured HIV prevalence, incidence-related indicators, and viral suppression in participating countries, helping compare program records with broader population patterns.
The relationship between disease-specific investment and the wider health system is complex. HIV laboratories, procurement capacity, and trained personnel can support other services, including tuberculosis care and outbreak response. At the same time, separate reporting demands and donor-specific delivery arrangements can increase administrative workload. During the COVID-19 pandemic, HIV programs used approaches such as multimonth dispensing and community distribution to maintain treatment access. These experiences illustrated the importance of health-system resilience without establishing that every HIV investment automatically strengthens every part of a national system.
Results, measurement, and attribution
PEPFAR reports results through a combination of service statistics, surveys, expenditure information, and modeled estimates. These sources answer different questions. A count of people receiving treatment describes program reach. Viral suppression describes a clinical outcome among those measured. A decline in population mortality describes a broader change that may reflect treatment expansion alongside other influences. Careful interpretation requires specifying the population, period, denominator, and method behind each indicator.
For fiscal year 2023, PEPFAR reported support for antiretroviral treatment for approximately 20.5 million people and stated that its investments had saved more than 25 million lives since 2003. The treatment figure is a programmatic service measure, whereas “lives saved” is a cumulative estimate of deaths averted relative to an estimated alternative trajectory. The latter is not obtained by observing a directly identifiable set of people who would otherwise have died. Such estimates depend on assumptions about untreated HIV, treatment effects, and the course of the epidemic.
International HIV monitoring has commonly used the 95–95–95 targets developed by the Joint United Nations Programme on HIV/AIDS: 95 percent of people living with HIV know their status, 95 percent of those diagnosed receive treatment, and 95 percent of those treated achieve viral suppression. The denominators are nested. If all three targets are met, the implied share of all people living with HIV who are virally suppressed is
or about 86 percent. This differs from saying that 95 percent of all people living with HIV are suppressed.
Routine reporting has limitations. People can move between facilities, return after interruptions, or appear in records under different identifiers. Recorded retention can be distorted when a person transfers without documentation. Viral-suppression percentages may also appear high if they include only people with documented test results and exclude those who were not tested. Data-quality work therefore includes record reconciliation, assessment of missing results, and examination of whether reported totals correspond to unique individuals.
Independent evaluations have examined mortality and other outcomes using cross-country comparisons and changes over time. A 2009 study by Eran Bendavid and Jayanta Bhattacharya found an association between PEPFAR focus-country status and reductions in HIV-related deaths during the early implementation period. Later analyses examined wider adult mortality and longer follow-up. Such studies provide evidence beyond program self-reporting, but they are not randomized evaluations of the entire initiative. Selection of countries, concurrent donor investment, domestic policy changes, and economic conditions complicate causal attribution.
PEPFAR outcomes also overlap with those of partner governments, the Global Fund, and other contributors. A person receiving treatment may depend on a publicly staffed clinic, donor-financed medicines, and a laboratory supported by another institution. Adding all organizations’ reported beneficiaries can therefore double-count people. Evaluating the initiative requires distinguishing its financial contribution, its operational support, and the collective outcomes of the national HIV response.
Policy debates and long-term sustainability
PEPFAR has operated at the intersection of infectious-disease control, foreign assistance, domestic U.S. legislation, and partner-country health policy. Its initial emergency model prioritized rapid delivery of lifesaving services. As treatment cohorts expanded and survival improved, the central policy problem increasingly became how to maintain high-quality care for decades. This transition does not remove the emergency consequences of interruption: people already receiving therapy remain dependent on continuous access to effective medicines.
Early prevention rules generated debate about the relationship between statutory spending requirements and locally appropriate programming. U.S. Government Accountability Office reviews documented implementation difficulties associated with the abstinence-related spending requirement. Another contested provision required certain recipients of U.S. HIV assistance to adopt a policy explicitly opposing prostitution and sex trafficking. In 2013, the U.S. Supreme Court ruled that this requirement could not constitutionally be imposed on U.S.-based organizations in the manner challenged. A 2020 decision held that the same constitutional protection did not extend to legally distinct foreign affiliates. These decisions concerned funding conditions and organizational speech, not the clinical effectiveness of HIV services.
The balance between international implementing organizations and local institutions has been another recurring issue. Local governments and organizations can provide knowledge of national systems and affected communities, but direct management of donor funds requires financial controls, procurement systems, and reporting capacity. Expanding local implementation therefore involves both transferring resources and developing institutional capabilities. The proportion of funds passing through local organizations alone does not establish whether decision-making authority, technical expertise, or long-term financing has also shifted.
Sustainability includes several distinct dimensions. Financial sustainability concerns the ability to pay for medicines, staff, laboratories, and prevention. Programmatic sustainability concerns continued quality and access. Political and institutional sustainability concerns durable commitment, functioning governance, and public accountability. A country may perform well in one dimension while remaining vulnerable in another—for example, maintaining strong clinical services while relying heavily on external commodity financing.
The appropriate division between domestic and external financing varies with national income, epidemic burden, fiscal capacity, and competing health needs. A transition that is manageable in one country may cause service gaps in another. Integration with primary care can reduce duplication, but it also requires budgets, staff competencies, and systems that preserve HIV-specific expertise. Growing numbers of older people living with HIV add needs related to cardiovascular disease, cancer, and other chronic conditions to the existing treatment workload.
Scientific progress does not eliminate these institutional questions. New prevention products and more convenient treatment formulations require procurement, delivery systems, and equitable access. Meanwhile, existing tools remain unevenly available across locations and populations. The long-term operation of PEPFAR therefore depends on connecting biomedical advances with dependable financing, national institutions, community participation, and the uninterrupted care of people already enrolled in treatment.